(Q27852988)

English

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

PubMed publication ID

13 November 2016

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis (English)

1 reference

PubMed publication ID

13 November 2016

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

Christina Therkildsen

object named as

Christina Therkildsen

1

0 references

Troels K Bergmann

object named as

Troels K Bergmann

2

0 references

object named as

Steen Ladelund

4

0 references

object named as

Mef Nilbert

5

0 references

author name string

Tine Henrichsen-Schnack

3

0 references

publication date

July 2014

0 references

Acta Oncologica

0 references

53

0 references

7

0 references

852-64

0 references

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.3109/0284186X.2014.895036

21 April 2017

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.3109/0284186X.2014.895036

21 April 2017

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

1 reference

https://api.crossref.org/works/10.3109/0284186X.2014.895036

21 April 2017

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.3109/0284186X.2014.895036

21 April 2017

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

1 reference

https://api.crossref.org/works/10.3109/0284186X.2014.895036

21 April 2017

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

1 reference

https://api.crossref.org/works/10.3109/0284186X.2014.895036

21 April 2017

EGFR antagonists in cancer treatment

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 April 2017

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 April 2017

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 April 2017

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 April 2017

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Genomic and biological characterization of exon 4 KRAS mutations in human cancer

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Wild-Type KRAS and BRAF Could Predict Response to Cetuximab in Chinese Colorectal Cancer Patients

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Ras proteins: different signals from different locations

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.895036

21 January 2018

Identifiers

10.3109/0284186X.2014.895036

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27852988&oldid=1500962527"